Sunflower State Health Plan Earns 4-Star NCQA Rating
Sunflower State Health Plan, a subsidiary of Centene Corporation, received a 4 out of 5-star rating in the 2026 NCQA Medicaid Health Plan Ratings.
Stocks · News reference
Truist Adjusts Price Target on Centene to $82 From $80, Maintains Buy Rating
Truist has increased its price target for Centene Corporation from $80 to $82 while maintaining a Buy rating on the stock.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
US Department of Justice Intervenes in Whistleblower Lawsuit Against Centene Corporation
The U.S. government has intervened in a False Claims Act lawsuit alleging that Centene Corporation engaged in fraudulent Medicare Advantage enrollment practices.
Goldman Sachs Adjusts Centene Price Target to $62 From $56
Goldman Sachs has revised its price target for Centene Corporation, increasing it from $56 to $62.
Deutsche Bank Adjusts Centene Price Target to $87 From $85
Deutsche Bank has raised its price target for Centene Corporation from $85 to $87 while maintaining a Buy rating.
Ambetter from Centene Reports Lowest Average Rate Increase in Missouri ACA Marketplace
Missouri regulators finalized 2027 health insurance marketplace rates, with Ambetter from Centene's Home State Health Plan reporting the smallest average premium increase in the state at just under 10%.
Wells Fargo Maintains Equal-Weight Rating on Centene and Raises Price Target
Wells Fargo has maintained its Equal-Weight rating on Centene Corporation while increasing its price target from $69 to $75.